ES2015717A6 - Un procedimiento para la preparacion de una composicion efervescente para administracion oral que contiene ranitidina. - Google Patents

Un procedimiento para la preparacion de una composicion efervescente para administracion oral que contiene ranitidina.

Info

Publication number
ES2015717A6
ES2015717A6 ES8902216A ES8902216A ES2015717A6 ES 2015717 A6 ES2015717 A6 ES 2015717A6 ES 8902216 A ES8902216 A ES 8902216A ES 8902216 A ES8902216 A ES 8902216A ES 2015717 A6 ES2015717 A6 ES 2015717A6
Authority
ES
Spain
Prior art keywords
pharmaceutical compositions
ranitidine
bicarbonate
pharmaceutical composition
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES8902216A
Other languages
English (en)
Inventor
Alain Emile Schaeffer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoire Glaxo Wellcome SA
Original Assignee
Laboratoires Glaxo SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Glaxo SA filed Critical Laboratoires Glaxo SA
Publication of ES2015717A6 publication Critical patent/ES2015717A6/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0002Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0007Effervescent
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

UN PROCEDIMIENTO PARA LA PREPARACION DE UNA COMPOSICION FARMACEUTICA EFERVESCENTE PARA ADMINISTRACION POR VIA ORAL, UTIL COMO ANTAGONISTA DEL RECEPTOR HSI2 DE LA HISTAMINA, QUE CONSISTE EN PREPARAR UNA MEZCLA CON GRANULACION SI SE DESEA, A PARTIR DE RANITIDINA O UNA SAL FISIOLOGICAMENTE ACEPTABLE DE LA MISMA, UN CARBONATO O BICARBONATO ALCALINO Y UN CITRATO DE MONOMETAL ALCALINO, JUNTO CON LOS VEHICULOS Y EXCIPIENTES ADECUADOS, Y COMPRIMIR LA MEZCLA O GRANULADO.
ES8902216A 1988-06-24 1989-06-23 Un procedimiento para la preparacion de una composicion efervescente para administracion oral que contiene ranitidina. Expired - Lifetime ES2015717A6 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8808497A FR2633181B1 (fr) 1988-06-24 1988-06-24 Composition pharmaceutique a base de ranitidine et son procede de preparation

Publications (1)

Publication Number Publication Date
ES2015717A6 true ES2015717A6 (es) 1990-09-01

Family

ID=9367671

Family Applications (1)

Application Number Title Priority Date Filing Date
ES8902216A Expired - Lifetime ES2015717A6 (es) 1988-06-24 1989-06-23 Un procedimiento para la preparacion de una composicion efervescente para administracion oral que contiene ranitidina.

Country Status (32)

Country Link
US (1) US5102665A (es)
JP (1) JPH0786086B2 (es)
KR (1) KR940002662B1 (es)
AT (1) AT396426B (es)
AU (1) AU627194B2 (es)
BE (1) BE1005691A4 (es)
CA (1) CA1329130C (es)
CH (1) CH679276A5 (es)
CY (1) CY1637A (es)
CZ (1) CZ280886B6 (es)
DE (1) DE3920626C2 (es)
DK (1) DK170223B1 (es)
ES (1) ES2015717A6 (es)
FR (1) FR2633181B1 (es)
GB (1) GB2219940B (es)
HK (1) HK33192A (es)
HU (1) HU210067A9 (es)
IE (1) IE60725B1 (es)
IL (1) IL90731A (es)
IT (1) IT1232149B (es)
LU (1) LU87541A1 (es)
MY (1) MY106412A (es)
NL (1) NL8901596A (es)
NZ (1) NZ229698A (es)
PH (1) PH26018A (es)
PT (1) PT90962B (es)
SA (1) SA90100095B1 (es)
SE (1) SE502285C2 (es)
SG (1) SG21892G (es)
SK (1) SK403891A3 (es)
ZA (1) ZA894787B (es)
ZW (1) ZW7889A1 (es)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU627775B2 (en) * 1988-09-20 1992-09-03 Glaxo Group Limited Pharmaceutical compositions
DE4027927A1 (de) * 1990-09-04 1992-03-05 Bayer Ag Brausekomponente und verfahren zu ihrer herstellung
GB9019875D0 (en) * 1990-09-11 1990-10-24 Glaxo Group Ltd Pharmaceutical compositions
CA2055661A1 (en) * 1990-12-21 1992-06-22 Manley A. Paulos Treatment of upset stomach associated with heartburn, sour stomach or acid indigestion with an effervescent h2 blocker formulation
US5629013A (en) * 1991-04-04 1997-05-13 The Procter & Gamble Company Chewable calcium carbonate antacid tablet compositions
FR2700669B1 (fr) * 1993-01-22 1995-04-14 Tassoni Jean Pierre Composition effervescente pour la préparation de boissons gazeuses.
US5503846A (en) * 1993-03-17 1996-04-02 Cima Labs, Inc. Base coated acid particles and effervescent formulation incorporating same
US5407687A (en) * 1994-02-22 1995-04-18 Glaxo Inc. Ranitidine solid dosage form
IL112779A (en) * 1994-03-01 1999-11-30 Gergely Gerhard Granular product or tablet containing an efferescent system and an active pharmaceutical substance and its preparation
US5538737A (en) * 1994-11-30 1996-07-23 Applied Analytical Industries, Inc. Oral compositions of H2 -antagonists
SE512835C2 (sv) * 1996-01-08 2000-05-22 Astrazeneca Ab Doseringsform innehållande en mångfald enheter alla inneslutande syralabil H+K+ATPas-hämmare
JP2000511178A (ja) * 1996-05-17 2000-08-29 メルク エンド カンパニー インコーポレーテッド 発泡性ビスホスホネート製剤
US5728401A (en) * 1997-04-16 1998-03-17 Ranbaxy Laboratories, Ltd. Effervescent ranitidine formulations
HUP9701293A3 (en) * 1997-07-25 1999-08-30 Chinoin Gyogyszer Es Vegyeszet New salts without unsavoury taste and pharmaceutical compositions containing them
US6974590B2 (en) 1998-03-27 2005-12-13 Cima Labs Inc. Sublingual buccal effervescent
US20030091629A1 (en) * 1998-03-27 2003-05-15 Cima Labs Inc. Sublingual buccal effervescent
US6264984B1 (en) 1999-12-06 2001-07-24 Bristol-Myers Squibb Company Effervescent histamine H2 antagonist composition
JP2001253826A (ja) * 2000-03-09 2001-09-18 Maruzen Pharmaceut Co Ltd 内服用剤
WO2002089823A1 (fr) * 2001-04-27 2002-11-14 Kyoto Pharmaceutical Industries, Ltd. Methode de conservation pour un suppositoire
US20030104017A1 (en) * 2001-10-26 2003-06-05 Boehringer Ingelheim International Gmbh Epinastine formulation for oral administration
AU2003284942A1 (en) * 2002-10-30 2004-06-07 Pharmacia Corporation Oral extended release tablets and methods of making and using the same
US20050089502A1 (en) * 2003-08-21 2005-04-28 Todd Schansberg Effervescent delivery system
US7862833B2 (en) * 2003-12-31 2011-01-04 Cima Labs, Inc. Effervescent oral opiate dosage forms and methods of administering opiates
WO2005065317A2 (en) * 2003-12-31 2005-07-21 Cima Labs Inc. Effervescent oral fentanyl dosage form
US20050142197A1 (en) * 2003-12-31 2005-06-30 Cima Labs Inc. Generally linear effervescent oral fentanyl dosage form and methods of administering
US8216610B2 (en) * 2004-05-28 2012-07-10 Imaginot Pty Ltd. Oral paracetamol formulations
EP1750677B1 (en) * 2004-05-28 2017-02-01 Imaginot Pty Ltd. Oral therapeutic compound delivery system
US20060100271A1 (en) * 2004-11-08 2006-05-11 Keith Whitehead Stabilized aqueous ranitidine compositions
EP3263117A1 (en) * 2005-11-28 2018-01-03 Imaginot Pty Ltd. Oral therapeutic compound delivery system
CN101484132A (zh) * 2007-07-09 2009-07-15 柏树制药公司 具有合意口味的雷尼替丁制剂
KR20170003414A (ko) * 2015-06-30 2017-01-09 (주)아모레퍼시픽 속붕해형 과립환 모발 세정용 조성물
CN105997922A (zh) * 2016-06-12 2016-10-12 佛山市腾瑞医药科技有限公司 一种盐酸雷尼替丁泡腾片及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1962791A1 (de) * 1969-12-15 1971-06-24 Boehringer Mannheim Gmbh Brausetabletten,Brausepulver und Verfahren zur Herstellung derselben
GB8313217D0 (en) * 1983-05-13 1983-06-22 Glaxo Group Ltd Pharmaceutical compositions
NZ215069A (en) * 1985-03-01 1988-06-30 Reckitt & Colmann Prod Ltd Pharmaceutical composition with histamine h 2 -receptor antagonist
FR2593065B1 (fr) * 1986-01-22 1988-09-09 Smith Kline French Lab Couples effervescents, compositions effervescentes d'antagonistes h2 de l'histamine les contenant et leur preparation.
GB8909793D0 (en) * 1989-04-28 1989-06-14 Beecham Group Plc Pharmaceutical formulation

Also Published As

Publication number Publication date
PT90962A (pt) 1989-12-29
IE60725B1 (en) 1994-08-10
PH26018A (en) 1992-01-29
DK170223B1 (da) 1995-07-03
NL8901596A (nl) 1990-01-16
SE8902288L (sv) 1989-12-25
NZ229698A (en) 1991-05-28
IT1232149B (it) 1992-01-25
ZA894787B (en) 1990-03-28
MY106412A (en) 1995-05-30
SK278823B6 (sk) 1998-03-04
GB2219940B (en) 1992-01-02
HK33192A (en) 1992-05-15
BE1005691A4 (fr) 1993-12-21
JPH0245421A (ja) 1990-02-15
US5102665A (en) 1992-04-07
DE3920626C2 (de) 1994-12-22
LU87541A1 (fr) 1990-02-28
CZ280886B6 (cs) 1996-04-17
IL90731A0 (en) 1990-01-18
FR2633181B1 (fr) 1992-01-10
SA90100095B1 (ar) 1999-06-30
FR2633181A1 (fr) 1989-12-29
AU3674489A (en) 1990-01-04
CA1329130C (en) 1994-05-03
IE892047L (en) 1989-12-24
HU210067A9 (en) 1995-02-28
CY1637A (en) 1992-11-06
SG21892G (en) 1992-04-16
ATA154489A (de) 1993-01-15
AU627194B2 (en) 1992-08-20
DK314089D0 (da) 1989-06-23
IT8948116A0 (it) 1989-06-22
KR910000100A (ko) 1991-01-29
ZW7889A1 (en) 1990-02-21
DE3920626A1 (de) 1989-12-28
GB8914428D0 (en) 1989-08-09
SE502285C2 (sv) 1995-09-25
SE8902288D0 (sv) 1989-06-22
PT90962B (pt) 1994-12-30
JPH0786086B2 (ja) 1995-09-20
AT396426B (de) 1993-09-27
GB2219940A (en) 1989-12-28
IL90731A (en) 1994-04-12
CZ403891A3 (en) 1993-08-11
DK314089A (da) 1989-12-25
KR940002662B1 (ko) 1994-03-28
SK403891A3 (en) 1998-03-04
CH679276A5 (es) 1992-01-31

Similar Documents

Publication Publication Date Title
MY106412A (en) Pharmaceutical compositions.
BG104841A (en) Fizzy formulations
IL109186A0 (en) Stable, ingestable and absorbable nadh and nadph therapeutic compositions
NZ502280A (en) Combination therapy comprising atorvastatin and an antihypertensive agent
DK1003486T3 (da) Farmaceutisk præparat indeholdende et bruse-syre-basepar
MD872G2 (ro) Compoziţie farmaceutică efervescentă şi preparat pe baza ei, procedeu de fabricare a preparatului
NZ533252A (en) Treatment of wounds and compositions employed
EP0578823A4 (en) POROUS SOLID PREPARATION CONTAINING A PHYSIOLOGICALLY ACTIVE PROTEIN SUBSTANCE.
IT1217445B (it) Composizione farmaceutiche orosolubili contenti acetilcisteina
NZ511085A (en) Oral pharmaceutical compositions containing buprenorphin
MY119722A (en) Swallow tablet comprising paracetamol.
GB9007945D0 (en) Pharmaceutical formulation
ZA994998B (en) Combination of zinc ions and vitamin C and method of making.
CA2050970A1 (en) Pharmaceutical compositions containing furan derivatives
AU620218B2 (en) Anti-hiv drug
AU2615795A (en) Compounds and compositions for administration via oral inhalation or insufflation
GB9905663D0 (en) Iodine preparation composition
GB1475861A (en) Pharmaceutical composition
GB2251620B (en) (S)-11-Hydroxy-10-methylaporphine, its physiologically acceptable salts and pharmaceutical compositions thereof
IL97211A0 (en) Pharmaceutical composition comprising bisoprolol
IT1271398B (it) Composizioni farmaceutiche contenenti derivati polipeptidici del ferro per la terapia marziale
MX9606041A (es) Forma de dosificacion de rapida disolucion.

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20100315